Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 11/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681849 | 0.85 | GAA (0.53) | APLNRALDH1A1GAA | |
| SCHEMBL6505236 | 0.81 | GPR84 (0.43) | APLNRGPR84DAO | |
| SCHEMBL6493164 | 0.81 | GPR84 (0.43) | APLNRGPR84DAOALDH1A1 | |
| SCHEMBL7686694 | 0.80 | GPR84 (0.42) | GPR84DAOALDH1A1 | |
| SCHEMBL7681845 | 0.80 | GPR84 (0.42) | GPR84DAO | |
| SCHEMBL6490987 | 0.78 | GPR84 (0.40) | GPR84DAO | |
| SCHEMBL7677691 | 0.75 | DDB1 (0.46) | GPR84ELANEALDH1A1GAA | |
| SCHEMBL6491353 | 0.72 | KMT2A (0.41) | GPR84DAO | |
| SCHEMBL6498798 | 0.72 | HCAR1 (0.43) | GPR84ALOX5DAO | |
| SCHEMBL7682918 | 0.71 | HCAR1 (0.40) | GPR84ALOX5ELANEALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G. D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-6630497-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO | 2003-10-07 | — | — | US | disclosed |
| EP-0690854-B1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0664802-B1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0978515-A2 | 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1994021629-A1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | APLNR 1207/4885SLC2A1 2846/4885GPR84 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.